Eli Lilly has introduced its diabetes and weight-loss medication, Mounjaro (tirzepatide), to the Indian market following approval from the Central Drugs Standard Control Organisation (CDSCO). This launch addresses India’s escalating obesity and diabetes rates, offering a novel treatment option for patients.
Understanding Mounjaro
Mounjaro is a once-weekly injectable prescription medicine designed to manage type 2 diabetes and aid in weight loss. It functions by targeting both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, thereby enhancing insulin production and reducing appetite.
Pricing and Accessibility
In India, Mounjaro is available in single-dose vials with the following pricing:
- 2.5 mg vial: ₹3,500
- 5 mg vial: ₹4,375
This translates to a monthly treatment cost ranging from ₹14,000 to ₹17,500, depending on the prescribed dosage.
Market Potential
India’s weight management market is on a significant growth trajectory. In 2024, the market was valued at $25.2 billion and is projected to reach $55.9 billion by 2033, reflecting a compound annual growth rate (CAGR) of 8.79%. This expansion is driven by increasing obesity rates and a heightened focus on health and wellness.
Competitive Landscape
Eli Lilly’s entry is set to invigorate competition among pharmaceutical companies aiming to capture a share of India’s burgeoning weight-loss market. Notable developments include:
- Novo Nordisk plans to introduce its weight-loss drug, Wegovy, by 2026 as its active ingredient, semaglutide, is set to go off-patent in India.
- Sun Pharmaceutical is developing Utreglutide (GL0034), a GLP-1 receptor agonist for weight loss and type 2 diabetes, with a launch anticipated within the next five years.
- Biocon is creating its version of Wegovy as the drug loses exclusivity next year.
Additionally, companies like Zydus Lifesciences, Cipla, Dr. Reddy’s, Lupin, Natco Pharma, Mankind Pharma, and Aurobindo Pharma are developing generic versions of semaglutide, anticipating high demand in India’s growing obesity treatment market.
The introduction of Mounjaro into the Indian market represents a significant advancement in addressing the country’s obesity and diabetes challenges. As pharmaceutical companies continue to innovate and introduce new treatments, patients will benefit from a broader range of options to manage their health effectively.
Reference:
The Indian Express+3Reuters+3Biz & Finance News+3Reuters+1Reuters+1
